Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy
Feasibility and Safety of Dexmedetomidine Sedation for Patients presenting for Awake Fibreoptic Bronchoscopy
Keat Lee
100 participants
Dec 15, 2008
Interventional
Conditions
Summary
We aim to trial dexmedetomidine as a sedating agent for awake diagnostic fibreoptic bronchoscopy. It has a number of unique properties which we feel would be useful - sedating, reduces discomfort and stress during potentially uncomfortable procedures. We would be monitoring for any problems or adverse events during this trial.
Eligibility
Inclusion Criteria2
- years and above, Presenting for awake fibreoptic bronchoscopy, and
- Not pregnant at the start of the procedure/sedation
Exclusion Criteria1
- Allergy to dexmedetomidine,2nd degree heart block and above,Hypovolaemia,Hypotensive at the start of the procedure/sedation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine sedation as an intravenous infusion to obtain sedation. Initial bolus of 0.5mcg/kg over 10 minutes followed by an infusion of 0.2-0.7mcg/kg/h, titrating to a Ramsay Sedation Score of 4 during the procedure. This infusion would be ceased once bronchoscopy is completed. The estimated time for the bronchoscopy would be about 15-20 minutes.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000304336